SCHEMBL4259121

SCHEMBL4259121

NC(=O)c1ccc(Cl)cc1Cl.O=S(=O)(O)/C=C/c1ccc(Cl)nc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 7/20 0.53
KDM4E B2RXH2 2/20 0.40
MAPT P10636 2/20 0.40
ALDH1A1 P00352 2/20 0.38
MAPK1 P28482 1/20 0.38
HIF1A Q16665 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
HTT P42858 2/20 0.37
NPC1 O15118 1/20 0.37
PKM P14618 1/20 0.37
HPGD P15428 1/20 0.37
NFKB1 P19838 1/20 0.37
RAB9A P51151 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37
TSHR P16473 1/20 0.37
CASP1 P29466 1/20 0.37
NNMT P40261 1/20 0.36
MKNK1 Q9BUB5 1/20 0.36
MKNK2 Q9HBH9 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4618879 0.86 SMN1; SMN2 (0.44) KDM4EMAPTALDH1A1MAPK1HIF1A
SCHEMBL4258557 0.85 MAOA (0.44) NFE2L2NNMTMKNK1MKNK2KMT2A
SCHEMBL4256653 0.85 P2RX7 (0.46) NFE2L2KDM4EMAPTL3MBTL1FLT1
SCHEMBL4261098 0.83 KMT2A (0.42) NFE2L2KDM4EMAPTALDH1A1MAPK1
SCHEMBL4620100 0.83 FLT1 (0.44) KDM4EMAPTALDH1A1SMN1; SMN2HTT
SCHEMBL4619266 0.83 AR (0.46) KDM4EMAPTALDH1A1MAPK1HIF1A
SCHEMBL4258009 0.82 KMT2A (0.56) NFE2L2KDM4EMAPTALDH1A1MAPK1
SCHEMBL4265110 0.81 NFE2L2 (0.50) NFE2L2KDM4EMAPTALDH1A1SMN1; SMN2
SCHEMBL4618030 0.81 SMN1; SMN2 (0.49) NFE2L2KDM4EMAPTALDH1A1SMN1; SMN2
SCHEMBL4618986 0.81 PPARG (0.47) KDM4EMAPTALDH1A1SMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904471-B1 HETEROARYLETHENYL DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS HOFFMANN LA ROCHE (CH) 2009-10-21 EP claimed
US-7208506-B2 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US claimed
US-20070010564-A1 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. 2007-01-11 US claimed
EP-1904471-B1 HETEROARYLETHENYL DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS HOFFMANN LA ROCHE (CH) 2009-10-21 EP disclosed
US-7208506-B2 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US disclosed
US-20070010564-A1 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010564-A1 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents CYP3A43, CYP1A1, CYP3A5 NFE2L2 270/4885KDM4E 2160/4885MAPT 4626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.